Donatella Schena

Verona, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 68 publications

The Italian Trend of Contact Allergy to 2-Hydroxyethyl Methacrylate: Is the Current European Legislation Working?

The Italian Trend of Contact Allergy to 2-Hydroxyethyl Methacrylate: Is the Current European Legislation Working?

Journal: Contact dermatitis

Published: January 16, 2025

Effective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: A multicenter case series study.

Effective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: A multicenter case series study.

Journal: Journal of the American Academy of Dermatology

Published: March 17, 2024

Fast and safe clinical response to sonidegib in a 98-year old woman affected by locally advanced basal cell carcinoma.

Fast and safe clinical response to sonidegib in a 98-year old woman affected by locally advanced basal cell carcinoma.

Journal: Dermatology online journal

Published: March 12, 2024

Hand eczema in Italian patients referred for patch testing: A retrospective SIDAPA study (2016-2023).

Hand eczema in Italian patients referred for patch testing: A retrospective SIDAPA study (2016-2023).

Journal: Contact dermatitis

Published: March 09, 2024

Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis.

Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis.

Journal: Journal of clinical medicine

Published: December 24, 2023

Correction to: AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History.

Correction to: AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History.

Journal: American journal of clinical dermatology

Published: November 07, 2023

Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study.

Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study.

Journal: Journal of the American Academy of Dermatology

Published: October 14, 2023

Contact allergy to SIDAPA baseline series allergens in patients with eyelid dermatitis: An Italian multicentre study.

Contact allergy to SIDAPA baseline series allergens in patients with eyelid dermatitis: An Italian multicentre study.

Journal: Contact dermatitis

Published: September 22, 2023

AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History.

AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History.

Journal: American journal of clinical dermatology

Published: August 28, 2023

A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years.

A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years.

Journal: The Journal of dermatological treatment

Published: August 15, 2023

Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.

Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.

Journal: American journal of clinical dermatology

Published: August 02, 2023

Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study.

Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study.

Journal: The Journal of dermatological treatment

Published: July 14, 2023

Showing 1-12 of 68

Last Updated: 09/26/2026